While the majority of studies investigating the relationship between BRAF mutations and clinical outcomes are focused on patients with metastatic disease, recent studies have demonstrated that BRAF‐mutant melanomas are also associated with a shorter disease‐free and melanoma‐specific survival in patients with early‐stage disease 24, 25. Here, BRAF is linked to melanoma.